Metformin ameliorates core deficits in a mouse model of fragile X syndrome

Abstract

Fragile X syndrome (FXS) is the leading monogenic cause of autism spectrum disorders (ASD). Trinucleotide repeat expansions in FMR1 abolish FMRP expression, leading to hyperactivation of ERK and mTOR signaling upstream of mRNA translation. Here we show that metformin, the most widely used drug for type 2 diabetes, rescues core phenotypes in Fmr1−/y mice and selectively normalizes ERK signaling, eIF4E phosphorylation and the expression of MMP-9. Thus, metformin is a potential FXS therapeutic.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Chronic metformin treatment corrects the social deficit, repetitive behavior, aberrant dendritic spine morphology and exaggerated LTD in Fmr1−/y mice.
Figure 2: Chronic metformin treatment corrects macroorchidism, decreases translation and reduces the phosphorylation of upstream eIF4E effectors.

References

  1. 1

    Gkogkas, C.G. et al. Cell Rep. 9, 1742–1755 (2014).

  2. 2

    Hou, L. et al. Neuron 51, 441–454 (2006).

  3. 3

    Dziembowska, M. et al. Am. J. Med. Genet. A. 161A, 1897–1903 (2013).

  4. 4

    Leigh, M.J. et al. J. Dev. Behav. Pediatr. 34, 147–155 (2013).

  5. 5

    Sidhu, H., Dansie, L.E., Hickmott, P.W., Ethell, D.W. & Ethell, I.M. J. Neurosci. 34, 9867–9879 (2014).

  6. 6

    Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Cell Metab. 20, 953–966 (2014).

  7. 7

    Ming, M. et al. PLoS One 9, e114573 (2014).

  8. 8

    Wang, J. et al. Cell Stem Cell 11, 23–35 (2012).

  9. 9

    Soares, H.P., Ni, Y., Kisfalvi, K., Sinnett-Smith, J. & Rozengurt, E. PLoS One 8, e57289 (2013).

  10. 10

    Łabuzek, K. et al. Pharmacol. Rep. 62, 956–965 (2010).

  11. 11

    Hagerman, R., Au, J. & Hagerman, P. J. Neurodev. Disord. 3, 211–224 (2011).

  12. 12

    Bhattacharya, A. et al. Neuron 76, 325–337 (2012).

  13. 13

    Osterweil, E.K. et al. Neuron 77, 243–250 (2013).

  14. 14

    Udagawa, T. et al. Nat. Med. 19, 1473–1477 (2013).

  15. 15

    Li, J., Benashski, S.E., Venna, V.R. & McCullough, L.D. Stroke 41, 2645–2652 (2010).

  16. 16

    Khang, R., Park, C. & Shin, J.H. Neurosci. Lett. 579, 145–150 (2014).

  17. 17

    Jin, J. et al. Neuromolecular Med. 18, 581–592 (2016).

  18. 18

    Singh, J., Olle, B., Suhail, H., Felicella, M.M. & Giri, S. J. Neurochem. 138, 86–100 (2016).

  19. 19

    Lavoie, H. & Therrien, M. Nat. Rev. Mol. Cell Biol. 16, 281–298 (2015).

  20. 20

    Berry-Kravis, E. et al. Sci. Transl. Med. 8, 321ra5 (2016).

  21. 21

    Monyak, R.E. et al. Mol. Psychiatry (2016).

  22. 22

    Forslund, K. et al. Nature 528, 262–266 (2015).

  23. 23

    Hsiao, E.Y. et al. Cell 155, 1451–1463 (2013).

  24. 24

    Gkogkas, C.G. et al. Nature 493, 371–377 (2013).

  25. 25

    McKinney, B.C., Grossman, A.W., Elisseou, N.M. & Greenough, W.T. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 136B, 98–102 (2005).

  26. 26

    Schmidt, E.K., Clavarino, G., Ceppi, M. & Pierre, P. Nat. Methods 6, 275–277 (2009).

  27. 27

    Mogil, J.S. et al. Pain 126, 24–34 (2006).

Download references

Acknowledgements

This work is supported by the FRAXA Research Foundation, Brain Canada/FNC, a CIHR foundation grant (FDN-148423) and Brain & Behavior Research Foundation grants (24365) to N.S.; a Wellcome Trust/Royal Society Sir Henry Dale grant (107687/Z/15/Z) to C.G.G.; the Canada Research Chair Program (950-231066) to J.-C.L.; and a Brain Canada/NeuroDevNet Postdoctoral Training Award to J.P.

Author information

I.G., A.K. and J.P. designed the experiments, performed data analysis and wrote the manuscript. I.G., A.K., J.P., A.A.-V., E.F., R.C., V.S., T.P., A.N., S.W., S.M.J., C.C., E.A.M. and C.G.G. designed and carried out experiments. A.S., V.T.T., I.A.G. and K.G. assisted with experiments. K.N. supervised the project. J.-C.L., C.G.G. and N.S. supervised the project, designed experiments and edited the manuscript. All authors revised the manuscript.

Correspondence to Nahum Sonenberg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figures and Tables

Supplementary Figures 1–17 and Supplementary Tables 1 and 2. (PDF 5149 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gantois, I., Khoutorsky, A., Popic, J. et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med 23, 674–677 (2017) doi:10.1038/nm.4335

Download citation

Further reading